Clinical Trials Browser

Leiomyosarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

NCT00845039 2018-07-02

FC-4

Phase 2 Terminated

4 enrolled 9 charts

Gastrointestinal

Colonic Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00503685 2018-06-06

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

Phase 2 Completed

65 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT00728949 2018-06-06

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Phase 2 Completed

93 enrolled 14 charts

Breast

Breast Neoplasms

NCT00906373 2018-06-04

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

Phase 2 Completed

47 enrolled 14 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00870870 2018-06-01

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Phase 2 Completed

64 enrolled 20 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00617734 2018-04-17

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Phase 2 Completed

97 enrolled 18 charts

Head & Neck

Head and Neck Neoplasms

NCT00683475 2014-10-16

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Phase 2 Completed

138 enrolled 17 charts

Genitourinary

Prostatic Neoplasms

NCT00970580 2013-09-16

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Phase 1 Completed

18 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00785941 2011-10-13

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

Phase 1 Completed

16 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

A Study in Non-Small Cell Lung Cancer

A Study of IMC-A12 in Advanced Solid Tumors

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

FC-4

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available